Mecasermin Rinfabate

N/A

Report date: 2024/06/13 15:07:42

Base Information

Drug NameMecasermin Rinfabate
Drug Alias Name林美卡舍明Insulin-like growth factor-I/insulin-like growth factor binding protein-3mecaserminum rinfabas美卡舍明-林菲培mecasermina rinfabato +[18] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInsulin-like growth factor I receptor stimulantsInsulin-like growth factor binding protein III stimulants
TargetsInsulin-like growth factor I receptorInsulin-like growth factor binding protein III
Therapy Area/IndicationsFailure to ThriveRetinopathy of PrematurityCerebral Intraventricular Hemorrhage +[8] 
Global Approved IndicationsFailure to Thrive
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2005/12/12
Country/TerritoryCanadaUnited StatesSlovakia +[24] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInsmed
China Registration ClassN/A

Develop Information

Active CompaniesShireOHB Neonatology LtdChiesi Farmaceutici SPA +[4] 
Inactive CompaniesInsmed IncUniversity Of Rochester
Active IndicationsRetinopathy of PrematurityCerebral Intraventricular HemorrhageBronchopulmonary Dysplasia +[4] 
Inactive IndicationsFailure to ThriveNoonan SyndromeMyotonic Dystrophy +[4] 

Other Information

ATC CodeH01AC05
Related LinksWikipediaDrugBankKEGG